0001662579-24-000014.txt : 20240215
0001662579-24-000014.hdr.sgml : 20240215
20240215170235
ACCESSION NUMBER: 0001662579-24-000014
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240213
FILED AS OF DATE: 20240215
DATE AS OF CHANGE: 20240215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adams Kendra
CENTRAL INDEX KEY: 0001991929
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39567
FILM NUMBER: 24644679
MAIL ADDRESS:
STREET 1: C4 THERAPEUTICS, INC.
STREET 2: 490 ARSENAL WAY, SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: C4 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662579
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 475617627
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (617) 231-0700
MAIL ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
4
1
wk-form4_1708034519.xml
FORM 4
X0508
4
2024-02-13
0
0001662579
C4 Therapeutics, Inc.
CCCC
0001991929
Adams Kendra
C/O C4 THERAPEUTICS, INC.
490 ARSENAL WAY #120
WATERTOWN
MA
02472
0
1
0
0
Chief Financial Officer
0
Common Stock
2024-02-13
4
F
0
1301
6.53
D
45339
D
Common Stock
2024-02-14
4
A
0
36700
0
A
82039
D
Stock Option (Right to Buy)
7.31
2024-02-14
4
A
0
165300
0
A
2034-02-13
Common Stock
165300
165300
D
Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person.
Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025.
The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024.
/s/ Jolie M. Siegel, Attorney-in-Fact
2024-02-15